Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DisCoVeRy: Treatments of COVID-19 in Hospitalized Adults
NCT04315948Phase 3Completed
- Sponsor
- Inserm
- Start
- Mar 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 7
01
Overview
A Phase 3 trial of remdesivir, lopinavir + ritonavir, interferon beta-1a, hydroxychloroquine, tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Inserm. Started Mar 2020; status: completed.
02
Drugs
remdesivirlopinavir + ritonavirinterferon beta-1ahydroxychloroquinetixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04315948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315948.